Vaccinogen Announces the Successful Acquisition of Key Management and Staff

Nov 10, 2007

Frederick, MD, USA – November 10, 2007 – Vaccinogen announced today the successful hiring of key management and staff. One of the new members of the management team is COO, Andrew L. Tussing, who has a track record of building businesses for over 20 years. Mr. Tussing was also actively involved in the capital formation effort for Vaccinogen. The company is also pleased to announce the hiring of: Martin Page as Vice President of Regulatory affairs, Iedo Beeksma as Managing Director of Manufacturing, Dinand van der Linde as Managing Director of Marketing (Europe), Leslie Ivy as Head of Human Resources, Wilda M. Hankins, as Executive Office Manager and Contracts Administrator. The Company anticipates the additional announcements of other key specialists that have particular expertise with OncoVAX® development and manufacturing.

Founded by Michael G. Hanna, Jr., Ph.D., The purpose of Vaccinogen is to focus on the development of immunotherapy products for the treatment of solid tumors and on the commercialization of autologous tumor vaccine products.
OncoVAX® is based on a platform that utilizes an autologous (patient’s own) cancer cells as an active specific immunotherapy (“ASI”) for adjuvant treatment of Stage II colon cancer following surgery. The vaccine comprises sterile, metabolically active, irradiated, non-tumorigenic autologous tumor cells, with or without fresh frozen BCG bacteria as an adjuvant. OncoVAX® is produced individually for each patient and is administered by four intradermal injections. The vaccine is prepared using a proprietary, sterile manufacturing process following surgical removal of the colon tumor.
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of the disease. Such an approach has already been successful in preventing a number of infectious diseases. In most cases immune stimulation creates a population of white blood cells that can kill tumor cells wherever they arise in the body, years after surgical removal of the original tumor.
Vaccinogen’s scientists prepare a vaccine from the patient’s own tumor. The cells are dissociated, irradiated to make them non-tumorigenic and administered to the patient by three weekly injections, starting four weeks after surgery. A booster vaccination is administered six months later.
About Vaccinogen
Vaccinogen is a biopharmaceutical company developing and commercializing cancer vaccines and other immunotherapeutic products. Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune and anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for the production of OncoVAX® vaccine.
Vaccinogen’s online press kit:
Andrew L. Tussing

print email rss